Technology ID
TAB-2907

T Cell-Based Adoptive Transfer Immunotherapy for Polyomavirus-Associated Pathologies

E-Numbers
E-166-2014-0
Lead Inventor
Barrett, John (NHLBI)
Co-Inventors
Chinnasamy, Dhanalakshmi (Donna) (NHLBI)
Muranski, Pawel (NHLBI)
Buck, Christopher (NCI)
Applications
Therapeutics
Therapeutic Areas
Oncology
Infectious Disease
Immunology
Development Stages
Pre-Clinical (in vitro)
Development Status
  • Early-stage
  • In vitro data available
Research Products
Antibodies
Lead IC
NHLBI
ICs
NHLBI
NCI
Available for licensing are methods to generate T cells responsive to multiple polyomaviruses. The resulting T cell populations could be useful in treating immunosuppressed individuals with polyomavirus infections or polyomavirus-associated pathologies such as Merkel cell carcinoma (MCC), polyomavirus-associated nephropathy (PVAN), hemorrhagic cystitis, progressive multifocal leukoencephalopathy (PML), and trichodysplasia spinulosa (TS). The methods could also be used to restore polyomavirus-specific immunity in immunocompromised individuals.
Commercial Applications
  • Immunotherapy for immunosuppressed individuals with polyomavirus-associated pathologies.
Competitive Advantages
  • Methods allow development of polyomavirus antigen-specific T cells.

Request More Info

Licensing Contact:
Shmilovich, Michael
shmilovm@nih.gov

Related Inventions

  • E-168-2011-0
  • E-549-2013-0

Patents

  • Patent Cooperation Treaty
    (PCT) PCT/US2015/059021
    Filed on 2015-11-04
  • US
    Provisional (PRV) 62/075,726
    Filed on 2014-11-05

Collaborations

  • Licensing
  • Collaboration

Collaboration Description

  • The National Heart, Lung, and Blood Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize methods to generate T cells responsive to multiple polyomaviruses. For collaboration opportunities, please contact Dr. Vincent Kolesnitchenko at kolesniv@nhlbi.nih.gov.
Date Published